Pharmion 2.0

After scoring a multi-billion dollar success with Pharmion Corp., the same management team is looking to duplicate the feat by creating another in-licensing company, Clovis Oncology Inc. But this time around, the team is starting in a buyer's market and is planning to take advantage of new tools to direct drug development toward specific populations.

The newco will start out with $145 million, from mostly the same venture backers that bankrolled Pharmion (see Ebb & Flow, A13). ...